tiprankstipranks
Indivior PLC (INDV)
NASDAQ:INDV
US Market
Want to see INDV full AI Analyst Report?

Indivior (INDV) Earnings Dates, Call Summary & Reports

206 Followers

Earnings Data

Report Date
Jul 23, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0.83
Last Year’s EPS
0.51
Same Quarter Last Year
Based on 4 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:Apr 30, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution and substantial financial improvement driven by SUBLOCADE (double-digit revenue growth, 20% dispense unit growth, record adjusted EBITDA up 112% and raised 2026 guidance). It also announced disciplined capital actions that improve the balance sheet and return capital to shareholders. Offsetting these positives were setbacks in early-stage R&D (INDV-6001 and INDV-2000 not advancing internally), expected gross-to-net pressure for 2026, and ongoing reliance on SUBLOCADE for growth. On balance, the favorable commercial and financial momentum and upgraded guidance materially outweigh the program setbacks and known headwinds.
Company Guidance
Management raised 2026 guidance to total net revenue of $1.215–$1.285 billion (midpoint $1.25B, ~+1% vs 2025), with SUBLOCADE net revenue now guided to $950–$990 million (midpoint $970M, +13% YoY) driven by planned mid‑teens dispense‑unit growth in 2026 (vs 7% in 2025); adjusted EBITDA is guided to $620–$660 million (midpoint $640M, +50% YoY) implying a ~51% margin at the midpoint (up ~16 percentage points vs 2025), operating expenses $430–$450 million, and expected cash flow from operations of approximately $340 million. They ended Q1 with $201 million of gross cash and investments, project forward leverage of ~0.8x (midpoint), completed a $500 million convertible note due 2031 (used to repay a $333 million term loan and reduce interest to 0.625% from 9.5%), repurchased 4 million shares for $125 million at an average $31.45 (leaving roughly $275 million on the $400 million buyback), expect full‑year gross margins in the mid‑80s, and noted a $14 million prior‑year gross‑to‑net release in Q1 but cautioned gross‑to‑net adjustments will be a headwind in 2026.
Strong Top-Line Growth
Total net revenue grew 19% year-over-year to $317 million in Q1 2026.
SUBLOCADE Revenue Acceleration
Total SUBLOCADE net revenue increased 32% year-over-year to $232 million (U.S. SUBLOCADE up 33% to $218 million), driven by 20% dispense unit growth and favorable price/mix.
Patient and Prescriber Momentum
Record new patient starts of ~31,800 in Q1 (up 29% YoY); over 500,000 U.S. patients prescribed SUBLOCADE since launch (nearly 25% added in the last 5 quarters); total U.S. SUBLOCADE patients treated in last 12 months: 191,600. Active SUBLOCADE prescribers grew 19% YoY; prescribers treating 5+ patients grew 20% YoY.
Adjusted EBITDA and Margin Expansion
Adjusted EBITDA was a record $164 million in Q1, up 112% YoY, with margin improvement of 23 percentage points. 2026 adjusted EBITDA guidance raised to $620–$660 million (midpoint $640M), up ~50% YoY and implying a ~51% margin.
Raised 2026 Financial Guidance
Total 2026 net revenue guidance raised to $1.215–$1.285 billion (midpoint up ~1% vs 2025). SUBLOCADE 2026 net revenue guidance raised to $950–$990 million (midpoint +13% YoY). Company now expects SUBLOCADE dispense unit growth to accelerate to mid-teens in 2026 (from 7% in 2025).
Operating Efficiency and Cost Reduction
Non-GAAP operating expenses were $116 million in Q1, down 21% YoY due to headcount reductions, R&D/medical affairs restructuring, and footprint consolidation.
Capital Deployment and Balance Sheet Improvements
Completed $500 million senior convertible notes offering (used mostly to repay $333 million term loan), lowering interest to 0.625% from 9.5%. Repurchased $125 million of shares (4 million shares at $31.45 avg); remaining buyback capacity reported (~$275M). Q1 gross cash & investments: $201 million; projected 2026 leverage ~0.8x and ~$340 million expected cash flow from operations.
Commercial Execution and DTC Impact
DTC campaign 'Move Forward in Recovery' showing early impact: >1,200 new CRM enrollments/month, >8,300 engaged consumers since launch, >30,000 Find-a-Provider searches in Q1, and paid search volumes above pre-campaign levels. Specialty pharmacy enhanced service agreements and improved dispense yields underway.

Indivior (INDV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

INDV Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 23, 2026
2026 (Q2)
0.83 / -
0.51
Apr 30, 2026
2026 (Q1)
0.66 / 0.96
0.41134.15% (+0.55)
Feb 26, 2026
2025 (Q4)
0.67 / 0.82
0.32156.25% (+0.50)
Oct 30, 2025
2025 (Q3)
0.41 / 0.72
0.5433.33% (+0.18)
Jul 31, 2025
2025 (Q2)
0.26 / 0.51
0.4415.91% (+0.07)
Apr 24, 2025
2025 (Q1)
0.23 / 0.41
0.3710.81% (+0.04)
Feb 20, 2025
2024 (Q4)
0.22 / 0.32
0.43-25.58% (-0.11)
Oct 24, 2024
2024 (Q3)
0.41 / 0.54
0.3458.82% (+0.20)
Jul 25, 2024
2024 (Q2)
0.40 / 0.44
0.3912.82% (+0.05)
Apr 25, 2024
2024 (Q1)
0.41 / 0.37
0.4-7.50% (-0.03)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

INDV Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 30, 2026
$34.15$36.78+7.70%
Feb 26, 2026
$33.63$33.71+0.24%
Oct 30, 2025
$25.24$29.13+15.41%
Jul 31, 2025
$17.40$20.20+16.09%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Indivior PLC (INDV) report earnings?
Indivior PLC (INDV) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
    What is Indivior PLC (INDV) earnings time?
    Indivior PLC (INDV) earnings time is at Jul 23, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is INDV EPS forecast?
          INDV EPS forecast for the fiscal quarter 2026 (Q2) is 0.83.